6397 RESULTS
Sort By:
A novel public-private consortium designed to combat Alzheimer’s disease by supporting the development of new animal models is seeking grant applications from scientists at universities and
The Food and Drug Administration’s advisory committee on peripheral and central nervous system drugs yesterday narrowly recommended that the FDA approve memantine for advanced stages of Alzheimer’s disease...
The ratio of phosphorylated tau (p-tau) to β-amyloid (Aβ) in the cerebrospinal fluid improves the ability to distinguish clinically defined Alzheimer's patients from normal subjects, according to a study...
Acetylcholinesterase (AChE), best known for hydrolyzing the neurotransmitter acetylcholine, is also found in the amyloid plaques that plague the brains of Alzheimer's patients. What part this protein has in progression of AD is unclear, but papers suggest...
Two similar studies funded by Eisai and Pfizer companies, the developer and US-promoter of the acetylcholinesterase inhibitor drug donepezil, suggest that their drug, already widely used for the treatment of Alzheimer’s disease, may also relieve symptoms of patients with vascular dementia...
Could biopsy of olfactory epithelium yield early warnings of Alzheimer's disease (AD)? This possibility was raised by George Perry and colleagues who report that oxidative damage to olfactory neurons could be a harbinger of impending AD...
Prions, those self-replicating proteins responsible for scrapie, mad cow disease, and some human neurologic diseases, have been notoriously difficult to pin down in the cell. Now, an international collaboration reports perhaps the most detailed localization study to date...
The scientist who helped discover one of the few drugs currently approved for the treatment of Alzheimer's disease has received the $100,000 Alzheimer's Drug Discovery Award for 2003...
Hope that thiazolidinedione agonists of PPARγ will prove beneficial for Alzheimer's patients (see <a href="/res/for/journal/galea/default.asp">ARF recent live discussion</a>) may be tempered slightly by a report...
Enabling Technologies 2003 Workshop Summary Recommendations: A Report from Bar Harbor 2003 Enabling Technologies for Alzheimer Disease Research: 2003 Bar Harbor Workshop
The first day of Enabling Technologies 2003 focused on the natural history of Alzheimer's disease, fundamental cell biology, and mechanisms of neurodegeneration.
Recommendations for future research from the Enabling Technologies for Alzheimer's Disease Workshop in Bar Harbor, Maine.
The risk of developing bipolar disorder appears to increase in people who carry a particular polymorphism of a transcription factor that aids in the clearance of "junk" protein from the endoplasmic reticulum...
Subtle changes in synaptic transmission are likely responsible for learning and memory, but the molecular cast of characters at play in this complex process is only partly known. Two papers in this week's Nature Neuroscience online introduce two new players...
Genetic polymorphisms in the major histocompatibility complex (MHC)—a group of proteins that help the immune system distinguish self from non-self—can profoundly influence the immune response mounted against an amyloid β vaccine...
No filters selected
